Shears L L, Kawaharada N, Tzeng E, Billiar T R, Watkins S C, Kovesdi I, Lizonova A, Pham S M
Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.
J Clin Invest. 1997 Oct 15;100(8):2035-42. doi: 10.1172/JCI119736.
In cardiac transplantation, chronic rejection takes the form of an occlusive vasculopathy. The mechanism underlying this disorder remains unclear. The purpose of this study was to investigate the role nitric oxide (NO) may play in the development of allograft arteriosclerosis. Rat aortic allografts from ACI donors to Wistar Furth recipients with a strong genetic disparity in both major and minor histocompatibility antigens were used for transplantation. Allografts collected at 28 d were found to have significant increases in both inducible NO synthase (iNOS) mRNA and protein as well as in intimal thickness when compared with isografts. Inhibiting NO production with an iNOS inhibitor increased the intimal thickening by 57.2%, indicating that NO suppresses the development of allograft arteriosclerosis. Next, we evaluated the effect of cyclosporine (CsA) on iNOS expression and allograft arteriosclerosis. CsA (10 mg/kg/d) suppressed the expression of iNOS in response to balloon-induced aortic injury. Similarly, CsA inhibited iNOS expression in the aortic allografts, associated with a 65% increase in intimal thickening. Finally, we investigated the effect of adenoviral-mediated iNOS gene transfer on allograft arteriosclerosis. Transduction with iNOS using an adenoviral vector suppressed completely the development of allograft arteriosclerosis in both untreated recipients and recipients treated with CsA. These results suggest that the early immune-mediated upregulation in iNOS expression partially protects aortic allografts from the development of allograft arteriosclerosis, and that iNOS gene transfer strategies may prove useful in preventing the development of this otherwise untreatable disease process.
在心脏移植中,慢性排斥反应表现为闭塞性血管病变。这种病症的潜在机制尚不清楚。本研究的目的是探讨一氧化氮(NO)在同种异体移植动脉硬化发展中可能发挥的作用。将主要和次要组织相容性抗原均存在强烈遗传差异的ACI供体大鼠主动脉移植到Wistar Furth受体大鼠体内进行移植。与同基因移植相比,发现28天时收集的同种异体移植组织中诱导型一氧化氮合酶(iNOS)的mRNA和蛋白以及内膜厚度均显著增加。用iNOS抑制剂抑制NO生成可使内膜增厚增加57.2%,表明NO可抑制同种异体移植动脉硬化的发展。接下来,我们评估了环孢素(CsA)对iNOS表达和同种异体移植动脉硬化的影响。CsA(10 mg/kg/d)可抑制对球囊诱导的主动脉损伤的iNOS表达。同样,CsA抑制主动脉同种异体移植中的iNOS表达,同时内膜增厚增加65%。最后,我们研究了腺病毒介导的iNOS基因转移对同种异体移植动脉硬化的影响。使用腺病毒载体转导iNOS可完全抑制未治疗受体和接受CsA治疗受体的同种异体移植动脉硬化的发展。这些结果表明,早期免疫介导的iNOS表达上调可部分保护主动脉同种异体移植组织免受同种异体移植动脉硬化的影响,并且iNOS基因转移策略可能被证明对预防这种原本无法治疗的疾病进程有用。